AgingResearch.NewsJoin free

Eyestem Research

CompanyIndia

Eyestem Research develops one asset, in phase 1 (Eyecyte-RPE in age-related macular degeneration). Mostly cell therapy; based in India.

1
Asset
Furthest stage
Phase 1
Raised
US$10m
1
Trial
1
Signal

Pipeline

1

  • Eyecyte-RPE

    Replaces damaged retinal pigment epithelial cells to support retinal function.

    Phase 1, Cell therapy, age-related macular degeneration, eye disease

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Evidence behind the mechanisms1
  • Trials1
  • Funding rounds and grants1
  • Signals1
  • Similar companies6

Intelligence